NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock News
$88.61
+0.87 (+0.99%)
At Close: Mar 27, 2024
Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings?
11:55am, Monday, 24'th Oct 2022 Zacks Investment Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. Operating expenses might have ju
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
11:47am, Monday, 24'th Oct 2022 Zacks Investment Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q3 earnings.
Assertio (ASRT) to Report Q3 Earnings: What's in the Cards?
09:21am, Monday, 24'th Oct 2022 Zacks Investment Research
Assertio Holdings' (ASRT) third-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Universal Health (UHS) to Post Q3 Earnings: What's in Store?
05:17pm, Friday, 21'st Oct 2022 Zacks Investment Research
Universal Health's (UHS) Q3 results are likely to reflect sound segmental performances resulting from a constant pursuit of expansion moves. However, high labor costs might partly offset the results.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
01:11pm, Friday, 21'st Oct 2022 Zacks Investment Research
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
4 Biotech Stocks Set to Outpace Q3 Earnings Estimates
10:32am, Friday, 21'st Oct 2022
Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.
What's in Store for Novartis (NVS) This Earnings Season?
04:26pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q3 Earnings Expected to Decline
02:02pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical CEO on the company's drug pricing strategy
07:45pm, Wednesday, 19'th Oct 2022
Cramer spoke with BioMarin Pharmaceutical CEO Jean-Jacques Bienaimé on Wednesday.
AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem
04:02pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Aveo Pharmaceuticals (AVEO) is set to be acquired by LG Chem for an aggregate amount of $566 billion. The deal is expected to close by early 2023. Stock up.
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly
03:42pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Akouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
02:01pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors
10:30pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp
Factors Setting the Tone for HCA Healthcare (HCA) Q3 Earnings
05:40pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
HCA Healthcare's (HCA) third-quarter results are expected to reflect better emergency room visits and outpatient surgeries, partly offset by the continued incidence of labor costs.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.